Ansun Biopharma Stock

ansunbiopharma.comHealthcare / BioTech & PharmaFounded: 2003Funding to Date: $165.2MM

Ansun Biopharma, founded in 2003, is a biopharmaceutical company seeking to develop innovative antiviral therapies. Ansun Biopharma's therapy is designed with the goal of utilizing a host-directed anti-viral biological product that aims to treat respiratory viral infections such as influenza virus, para influenza virus, and metapneumovirus. Ansun Biopharma is headquartered in San Diego, California.

Register for Details

For more details on financing and valuation for Ansun Biopharma, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for Ansun Biopharma.

Register Today

Team

Management Team

Nancy Chang Ph.D
Chief Executive Officer & Chairperson of the Board
Ivy Fan
Executive
George Wang
Chief Technology Officer
Mikael Havluciyan
Chief Legal Officer & Corporate Secretary
Stanley Lewis MD
Chief Medical Officer

Board Members

Allen Chao Ph.D
Karen Liu Ph.D
Nancy Chang Ph.D
Aimin Wu
Sinopharm Healthcare Fund
Donald Payne
Michael Chao MD
Dave Chenn
Michael Chang Ph.D
Yi Shi Ph.D
Lilly Asia Ventures

Other companies like Ansun Biopharma in the BioTech & Pharma sector

Sector
Last Round Est. Valuation
$3.67B
Sector
Last Round Est. Valuation
$8.45B
Sector
Last Round Est. Valuation
$500MM
Sector
Last Round Est. Valuation
$8.84B
Sector
Last Round Est. Valuation
$303.94MM
Sector
Last Round Est. Valuation
$1.01B
Sector
Last Round Est. Valuation
$4.74B

News Highlights

Chinese biotech firm Ansun BioPharma secures $80m Series B financing
Ansun aims to drive the global Phase 3 clinical trial of its experimental anti-viral medication.
Updated on: Oct 1, 2023